Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
A 2016 phase 1B clinical trial, investigating the efficacy of NSI-189 in a randomized, placebo-controlled study design, indicated significant effects of the drug as orally administered to individuals suffering from MDD either once, twice or three times per day
NIOD CAIS 3 Conflicts When using NIOD CAIS, you should avoid using the following products in the same routine
Contraindications and Precautions Absolute Contraindications: Known copper allergy or response Wilsons disease (copper body function disorder) Pregnancy (insufficient safety data, though no known risks) Breastfeeding (insufficient data) Known allergy to GHK-Cu or components Relative Contraindications (Use with Caution): Hemochromatosis or other metal body function disorders Active skin infections at injection/use sites Severe kidney or liver disease (may affect peptide body function) Copper Considerations Copper Content: The copper peptide ghk-cu contains copper as an essential component
Glutathione is an essential molecule produced by your body
Sikiric et al., 2001
What makes BPC-157 a useful tool for signaling pathway research
US$ 26.80
US$ 26.58
US$ 20.41
US$ 27.84